Pharmacogenomic testing relies on biomarkers—specific genetic sequences in DNA—that play crucial roles in drug metabolism and response within the body. These biomarkers help predict how individuals will metabolize medications, guiding personalized treatment approaches to optimize therapeutic outcomes and minimize adverse effects.
The U.S. Food and Drug Administration (FDA) maintains a comprehensive list of pharmacogenomic biomarkers that have been identified and validated for clinical use. These biomarkers serve as indicators of how an individual may respond to certain drugs based on their genetic profile.
Key Functions of Pharmacogenomic Biomarkers:
– Metabolism Prediction: Biomarkers identified by pharmacogenomic testing indicate how efficiently a person’s body metabolizes specific medications.
– Treatment Personalization: By analyzing these biomarkers, healthcare providers can tailor drug selection and dosage to maximize efficacy and safety for each patient.
– Enhanced Drug Safety: Understanding biomarkers helps mitigate risks of adverse drug reactions, ensuring safer medication use.
Augustus Laboratories and other leading institutions leverage these biomarkers to advance pharmacogenomic testing, providing insights that inform precise treatment decisions.
For a detailed list of FDA-recognized pharmacogenomic biomarkers and their applications, visit the FDA’s resource
[here]
(https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling).
- Antimicrobial Resistance is a Global Issue
- Molecular Diagnostics vs Standard of Care in Wound Management: A Retrospective Cohort Study
- Advancements in Molecular Diagnostics for Enhanced Wound Care Management
- Advancing Pediatric Treatment with Pharmacogenomic Testing
- Understanding Pharmacogenomics: Harnessing Genetic Technology for Personalized Medicine
